What beyond-the-pill services can we offer to ensure rapid patient access, followed by continued therapy use, to maximize our market share within the competitive immunology sector?

Our client is preparing to launch into the crowded immunology sector where next-gen products with comparable clinical profiles need to compete against entrenched blockbusters, such as Abbvie’s Humira, as well as significantly discounted biosimilars. Within this context, a robust non-clinical differentiation strategy is key to demonstrate differentiated value to payers and secure coverage at an economically viable price.

Eradigm mapped each competitor’s support program offering and conducted in-depth interviews with the programs’ curators to pinpoint which support services provide the most value across key customers. This enables us to curate a bespoke best-in-class support services model, with tactical recommendations as to how these services should be executed.